← FDA DRUG APPROVALS

FDA ANDA · ANDA211147

AZITHROMYCIN

Sponsor: ZYDUS LIFESCIENCES

APPLICATION
ANDA211147
TYPE
ANDA
ORIGINAL APPROVAL
2018-07-31
LATEST ACTION
2023-03-17
ROUTE
ORAL
DOSAGE FORM
FOR SUSPENSION
MARKETING STATUS
Prescription

Products

AZITHROMYCINPrescription
AZITHROMYCIN EQ 100MG BASE/5ML · FOR SUSPENSION · ORAL
AZITHROMYCINPrescription
AZITHROMYCIN EQ 200MG BASE/5ML · FOR SUSPENSION · ORAL

Approval history

2023-03-17Labeling · Supplement 6 · standardAP
2020-01-13Labeling · Supplement 3 · standardAP
2018-07-31UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →